Abstract
In the present study, an effort was made to design prolonged release Eudragit nanoparticles of brimonidine tartrate by double emulsion–solvent evaporation technique for the treatment of open-angle glaucoma. The effect of various formulation variables like initial drug amount, lecithin proportion, phase volume and pH, secondary emulsifier and polymer proportion were studied. Various process variables like energy and duration of emulsification, lyophilization on the characteristics of nanoparticles and in vitro drug release profile were studied. The selected formulations were subjected to in vivo intraocular pressure-lowering efficacy studies by administering aqueous dispersion of nanoparticles into the lower cul de sac of glaucomatous rabbits. The prepared Eudragit-based nanoparticles were found to have narrow particle size range and improved drug loading. The investigated process and formulation variables found to have significant effect on the particle size, drug loading and entrapment efficiency, and in vitro drug release profile of nanoparticles. The selected formulations upon in vivo ocular irritability and tolerability tests were found to be well tolerated with no signs of irritation. In vivo pharmacodynamic efficacy studies revealed that the selected nanoparticle formulations significantly improved the therapy as area under the ∆IOP vs. time curve [AUC(∆IOP vs.t)] showed several fold increase in intensity and duration of intraocular pressure (IOP) decrease. All the selected nanoparticle formulations were found to prolong the drug release in vitro and prolong IOP reduction efficacy in vivo, thus rendering them as a potential carrier in developing improved drug delivery systems for the treatment of glaucoma.
REFERENCES
Lee VHL, Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J Pharm Sci. 1979;68:673–84.
Patton TF, Robinson JR. Quantitative precorneal disposition of topical applied pilocarpine nitrate in rabbit eyes. J Pharm Sci. 1976;65:1295–301.
De S, Robinson D. Polymer relationships during preparation of chitosan–alginate and poly-l-lysine–alginate nanospheres. J Control Rel. 2003;89:101–12.
Gref R, Minamitake Y, Perracchia MT, Trubeskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600–3.
Merodio M, Espuelas MS, Mirshahi M, Arnedo A, Irache JM. Efficacy of Ganciclovir-loaded nanoparticles in human cytomegalovirus (HCMV)-infected cells. J Drug Target. 2002;10:231–8.
Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using poly lactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44:3562–9.
Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophtholmol Vis Sci. 2003;44:1192–200.
Santos ALG, Bochot A, Doyle A, Tsapis N, Siepmann J, Siepmann F, et al. Sustained release of nanosized complexes of poly ethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release. 2006;112:369–81.
Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41–50.
De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A. Int J Pharm. 2001;224:159–68.
De Campos AM, Diebold Y, Carvalho ELS, Sanchez A, Alonso MJ. Chitosan nano particles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21:803–10.
Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm. 2008;68:513–25.
Langer K, Mutschler E, Lambrecht G, Mayer D, Troschau G, Stieneker F, et al. Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: evaluation as drug delivery system for ophthalmic applications. Int J Pharm. 1997;158:219–31.
Masson V, Billardon P, Fessi H, Devissagaut JP, Puisieux F. Tolerance studies and pharrnacokinetic evaluation of indomethacin-loaded nanocapsules in rabbit eyes. Proc Int Symp Control Rel Bioact Mater. 1992;19:423.
Heussler ML, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal drug delivery systems for the eye: a comparison of the efficacy of three different polymers: polyisobutyl cyanoacrylate, polylactic-co-glycolic acid, polyepsilon-caprolacton. STP Pharma Sci. 1992;2:98–104.
De TK, Rodman DJ, Holm BA, Prasad PN, Bergey EJ. Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J Microencapsulation. 2003;20:361–74.
De TK, Bergey EJ, Chung SJ, Rodman DJ, Bharali DJ, Prasad PN. Polycarboxylic acid nanoparticles for ophthalmic drug delivery: an ex vivo evaluation with human cornea. J Microencapsulation. 2004;21:841–55.
Munk SA, Harcourt D, Arasasingham P. Analogs of UK 14,304: structural features responsible for 2-adrenoceptor activity. Bioorg Med Chem. 1995;5:1745–50.
Torris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8–14.
Burke J, Manlapaz C, Kharlamb A, Runde E, Padillo E, Spada C. Therapeutic use of alpha-2-adrenoceptor agonists in glaucoma. In: Alpha-2-adrenergic receptors: structure, function and therapeutic implications. In: S. Lanier and Limbird (eds). Harwood Academic: Reading, UK. 1996. pp 179–187.
Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41 suppl 1:S9–S18.
Cantor BL, Burke J. Drug evaluation: brimonidine. Expert Opin Investig Drugs. 1997;6:1063–83.
Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary angle glaucoma. Am J Ophthalmol. 2001;131:729–33.
Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol. 1996;41 Suppl 1:S39–46.
Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha-2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 2001;913:133–9.
Wheeler LA, Tatton M, Elstner M, Chalmers-Redman RME, Tatton WG. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through Akt (protein kinase B) dependent new synthesis of bcl-2. Invest Ophthalmol Vis Sci. 2001;42:S441.
Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48 Suppl 1:S47–51.
Lai R, Hassan D, Chun T. Neuroprotective effect of ocular hypotensive agent brimonidine, Xith Congress of the European Society of Ophthalmology. Budapest, 1997: 439–444.
Lafuente MP, Villegas-Perez MP, Mayor S, Aguilera ME, Miralles IJ, Vidal-Sanz M. Neuroprotective effects of brimonidine against ischemia induced retinal ganglion. Cell death: a dose response in vivo study. Exp Eye Res. 2002;74:181–9.
Pignatello R, Bucolo C, Puglisi G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci. 2002;91:2536–641.
Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–55.
Al-Kassas R. Design and in vitro evaluation of gentamicin–Eudragit microspheres intended for intra-ocular administration. J Microencapsulation. 2004;21:71–81.
Krinzar B, Mateovic T, Bogataj M, Mrhar A. The influence of chitosan on in vitro properties of eudragit RS microspheres. Chem Pharm Bull. 2003;51:359–64.
Bhagav P, Deshpande P, Pandey S, Chandran S. Development and validation of stability indicating UV spectrophotometric method for the estimation of brimonidine tartrate in pure form, formulations and preformulation studies. Der Pharmacia Lettre. 2010;2(3):106–22.
Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.
Percicot CL, Schnell CR, Debon C, Hariton C. Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: effects of Timolol, Dorzolamide, and Epinephrine. J Pharmacol Toxicol Methods. 1996;36:223–8.
Anumolu SS, Singh Y, Gao D, Stein S, Sinko JP. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release. 2009;137:152–9.
Fernandez DR, Ramirez JM, Trivino A, Sanchez D, Paraiso P, Garcia DLM, et al. Experimental glaucoma significantly decreases atrial natriuretic factor (ANF) receptors in the ciliary processes of the rabbit eye. Exp Eye Res. 1991;53:591–6.
Himber J, De Burlet G, Andermann G. Effects of adrenergic agents on alpha-chymotrypsin induced ocular hypertension in albino and pigmented rabbits: a comparative study. J Ocul Phurmacol. 1989;5:93–8.
ACKNOWLEDGEMENTS
This work is a part of a grant support (no: SR/FTP/L-42/2005) provided to Dr. Sajeev Chandran by Department of Science and Technology, Ministry of Science and Technology, Govt. of India, New Delhi, India. Authors are highly grateful to Dr. Sushil Yadav, veterinarian, BITS Pilani and Mr. Dilip Pandey, BITS Pilani, for their valuable help in conducting the animal studies. Authors are also thankful to FDC Ltd. Mumbai, India for the generous gift sample of brimonidine tartrate.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhagav, P., Upadhyay, H. & Chandran, S. Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation. AAPS PharmSciTech 12, 1087–1101 (2011). https://doi.org/10.1208/s12249-011-9675-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-011-9675-1